DGX
Quest Diagnostics IncorporatedNYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
22.21
PEG
1.60
P/B
3.07
P/S
2.00
EV/EBITDA
14.04
DCF Value
$221.12
FCF Yield
6.2%
Div Yield
1.6%
Margins & Returns
Gross Margin
33.2%
Operating Margin
14.1%
Net Margin
9.0%
ROE
13.9%
ROA
17.6%
ROIC
8.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.81B | $245.0M | $2.18 |
| FY 2025 | $11.04B | $992.0M | $8.75 |
| Q3 2025 | $2.82B | $245.0M | $2.16 |
| Q2 2025 | $2.76B | $282.0M | $2.47 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
0.65
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.